About Innova Captab Limited

Innova Captab Limited is an Indian pharmaceutical company with integrated capabilities across formulation R&D, manufacturing, CDMO services, and branded generics, nearing two decades of operations as of FY 2025. The company operates manufacturing facilities at Baddi (Himachal Pradesh), Kathua (Jammu), and acquired Sharon units at Dehradun and Taloja, spanning nine independent blocks across five sites at group level after commissioning the Kathua greenfield plant in FY 2025. Activities include CDMO services and products, domestic branded generics, international branded generics, and Sharon’s formulations and APIs platform aligned to global standards (WHO-GMP, EU-GMP, UK-MHRA). The company expanded into regulated markets such as the United Kingdom and Canada, with exports to 30 countries. As of March 31, 2025, Innova had 1,950 employees and two material subsidiaries: Univentis Medicare Limited and Sharon Bio-Medicine Limited; the branded network in India reaches over 2,20,000 touchpoints. Key milestones in FY 2025 include commercialization of the Kathua, Jammu greenfield facility (four blocks: Cephalosporin, Penem, Penicillin, General injectables), entry into parenterals and respules, and progressing a new R&D centre at Panchkula. For FY 2025, revenue from operations was Rs 1,243.68 crore, EBITDA Rs 198.20 crore, and PAT Rs 128.26 crore, reflecting 15.0% revenue growth and 35.9% PAT growth year-on-year, with ROE 13.4% and ROCE 13.6%.

Innova Captab Limited Business Segment

• CDMO Services and Products — Rs 659.89 crore (53.1%): Growth supported by over 200 clients, with ~80% revenue from partners engaged for more than five years; portfolio spans oral solids, injectables, and complex dosage forms.

• Domestic Branded Generics — Rs 230.70 crore (18.5%): Revenue up 20.8% YoY, supported by a distribution network of 2,20,000+ touchpoints nationwide.

• International Branded Generics — Rs 156.28 crore (12.6%): Revenue up 24.7% YoY; presence in regulated markets (UK, Canada) and wider emerging markets; exports to 30 countries.

• Sharon — Rs 196.80 crore (15.8%): Integration delivered cost optimisation and synergies; capabilities in formulations and APIs bolster international presence.

Domestic vs international (FY 2025 revenue from operations):

• India — Rs 890.60 crore (71.6%).

• International — Rs 353.08 crore (28.4%).

Innova Captab Limited Key Management

• Manoj Kumar Lohariwala — Chairman and Whole-Time Director.

• Vinay Lohariwala — Managing Director.

• Jayant Vasudeo Rao — Whole-Time Director.

• Lokesh Bhasin — Chief Financial Officer.

• Mukeshkumar Siyaram Singh — Deputy Chief Financial Officer (KMP).

• Neeharika Shukla — Company Secretary and Compliance Officer.

Latest Updates on Innova Captab Limited

• Commissioned greenfield manufacturing facility at Kathua, Jammu with four advanced blocks; enabled entry into large and small volume parenterals and respules.

• Qualified for New Central Sector Scheme incentives in J&K, including GST-linked incentive (up to 300% of eligible plant and machinery) and 6% p.a. capital interest subvention on eligible capex loans.

• Advanced expansion into regulated international markets, notably the United Kingdom and Canada, alongside semi-regulated geographies.

• Strengthened integration of Sharon, improving profitability and unlocking platform synergies across formulations and APIs.

• Progressed DSIR-approved Baddi R&D and nearing completion of new Panchkula R&D centre focused on generic and complex-generic development.

• Shifted registered office to 1513, 15th Floor, Satra Plaza, Sector-19D, Vashi, Navi Mumbai, 400 703, with effect from June 2, 2025.